Education
About Us
Working with TipRanks
Follow Us
CANC - AI Analysis
Top Page
Tema Oncology ETF (CANC)
Rating:62Neutral
Price Target:
$32.00
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid returns so far this year, reflecting strength in its holdings.
Focused Health Care Exposure
Nearly all assets are invested in the health care sector, which benefits from long-term growth trends in oncology.
High-Performing Holdings
Several top holdings, such as Genmab and BridgeBio Pharma, have shown strong gains, contributing positively to the fund.
Negative Factors
Sector Concentration Risk
The ETF is heavily concentrated in health care, making it vulnerable to sector-specific downturns.
Geographic Overweight in the U.S.
The fund has significant exposure to U.S. companies, limiting diversification across global markets.
Higher Expense Ratio
The ETF charges a relatively high expense ratio compared to broader market funds, which can reduce net returns over time.
CANC vs. SPDR S&P 500 ETF (SPY)
AUM86.10M
RegionGlobal
Expense Ratio0.75%
Beta0.90
IssuerTema
Inception DateAug 15, 2023
Dividend Yield2.38%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,853
30 Day Avg. Volume8,796
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.14Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering54
CANC Summary
The Tema Oncology ETF (Ticker: CANC) is an investment fund focused on companies in the health care sector, specifically those involved in cancer research and treatment. It includes well-known names like Eli Lilly & Co and Roche Holding, along with other firms developing innovative therapies and technologies in oncology. This ETF is designed for investors who want to support advancements in cancer care while potentially benefiting from the growth of this critical field. However, new investors should be aware that the ETF is heavily concentrated in health care, meaning its performance can be significantly affected by changes in the industry or regulatory challenges.
How much will it cost me?The Tema Oncology ETF has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the health care sector that requires expert research and selection of companies.
What would affect this ETF?The Tema Oncology ETF could benefit from advancements in cancer research and increased global demand for innovative treatments, as well as strong performance from top holdings like Eli Lilly and Roche, which are leaders in oncology. However, it may face challenges from regulatory hurdles, high development costs in the biotech sector, and potential economic downturns that could impact funding for healthcare innovation.
CANC Top 10 Holdings
The Tema Oncology ETF is laser-focused on the health care sector, with a global mix of biotech and pharmaceutical heavyweights driving its performance. BridgeBio Pharma is the standout, surging ahead thanks to strong product launches, while AstraZeneca and Roche Holding are steady contributors with robust pipelines and strategic growth initiatives. On the flip side, Exelixis is lagging, weighed down by weak technical indicators despite solid revenue growth. With its concentrated exposure to oncology innovators, this fund is a bet on the future of cancer treatment breakthroughs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 7.23% | $6.23M | $10.85B | 15.37% | 52 Neutral | |
| Eli Lilly & Co | 5.10% | $4.39M | $769.97B | -3.93% | 70 Outperform | |
| BridgeBio Pharma | 4.23% | $3.65M | $12.74B | 180.03% | 56 Neutral | |
| Roche Holding | 3.97% | $3.42M | $261.10B | 3.52% | 69 Neutral | |
| Genmab | 3.93% | $3.38M | $17.79B | 28.27% | 74 Outperform | |
| Novartis AG | 3.89% | $3.35M | CHF187.47B | 3.30% | 78 Outperform | |
| AstraZeneca | 3.88% | $3.34M | £194.71B | 12.08% | 75 Outperform | |
| Nuvalent | 3.88% | $3.34M | $7.42B | 14.11% | 43 Neutral | |
| Arcellx Inc | 3.74% | $3.22M | $4.77B | 0.28% | 56 Neutral | |
| Exelixis | 2.99% | $2.57M | $10.61B | 21.55% | 76 Outperform |
CANC Technical Analysis
Positive
―
Price Trends
28.35
Positive
27.07
Positive
25.78
Positive
Market Momentum
0.65
Positive
64.96
Neutral
59.58
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.00, equal to the 50-day MA of 28.35, and equal to the 200-day MA of 25.78, indicating a bullish trend. The MACD of 0.65 indicates Positive momentum. The RSI at 64.96 is Neutral, neither overbought nor oversold. The STOCH value of 59.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CANC.
CANC Peer Comparison
Comparison Results
Performance Comparison
CANC
Tema Oncology ETF
30.64
3.50
12.90%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents